{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"38.9","upperLimit":"50.4","value":"44.7"},{"groupId":"OG001","lowerLimit":"27.7","upperLimit":"38.7","value":"33.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"308"},{"groupId":"OG001","value":"309"}],"units":"Participants"}],"description":"PFS was defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first. Per RECIST 1.1, PD was defined as ≥ 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. Note: The appearance of one or more new lesions was also considered PD. PFS Rate was defined as the percentage of participants that were PFS event-free at Month 12. The PFS Rate per RECIST 1.1 as assessed by Investigator at Month 12 is presented.","dispersionType":"95% Confidence Interval","groups":[{"description":"On Day 1 of each 21-day cycle, participants received an intravenous (IV) infusion of pembrolizumab 200 mg for up to 35 cycles (up to approximately 2 years) PLUS Investigator choice of chemotherapy for up to 6 cycles (paclitaxel 175 mg/m\\^2 PLUS cisplatin 50 mg/m\\^2 WITH or WITHOUT bevacizumab 15 mg/kg per local label OR paclitaxel 175 mg/m\\^2 PLUS carboplatin Area Under the Curve (AUC) 5 for up to 6 cycles, WITH or WITHOUT bevacizumab 15 mg/kg per local label). All treatments were administered until disease progression or toxicity. Eligible participants who stopped the initial course of pembrolizumab with Stable Disease (SD) or better but progressed after discontinuation may have been able to initiate a second course of pembrolizumab for up to 17 cycles (up to approximately 1 additional year) at the investigator's discretion.","id":"OG000","title":"Pembrolizumab+Chemotherapy"},{"description":"On Day 1 of each 21-day cycle, participants received an IV infusion of placebo (Normal Saline or Dextrose solution) for up to 35 cycles (up to approximately 2 years) PLUS Investigator choice of chemotherapy for up to 6 cycles (paclitaxel 175 mg/m\\^2 PLUS cisplatin 50 mg/m\\^2 WITH or WITHOUT bevacizumab 15 mg/kg per local label OR paclitaxel 175 mg/m\\^2 PLUS carboplatin AUC 5 for up to 6 cycles, WITH or WITHOUT bevacizumab 15 mg/kg per local label). All treatments were administered until disease progression or toxicity.","id":"OG001","title":"Placebo+Chemotherapy"}],"paramType":"NUMBER","populationDescription":"All randomized participants based on the treatment group to which they were randomized.","reportingStatus":"POSTED","timeFrame":"12 months","title":"Percentage of Participants That Were PFS Event-Free (PFS Rate) at Month 12 Per RECIST 1.1 as Assessed by Investigator","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}